secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-07-31T20:06:04+00:00
Accession:  0001213900-26-083961
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio receives ~$4.6M in R&D rebates from Australia and UK, extends cash runway
--------------------------------------------------------------------------------

- Received ~$4.2M R&D cash rebate from Australia on July 30, 2026, plus ~$0.4M from UK in June 2026.
- Combined ~$4.6M in non-dilutive rebates exceeded net cash used in Q2 operating activities (after adjusting for UK rebate).
- Strengthens balance sheet and extends cash runway without issuing additional equity.
- Rebates support advancement of CORDStrom toward regulatory filings (MAA UK MHRA 2026, EU EMA 2027, US BLA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/0001213900-26-083961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/ea0300069-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-083961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer